Display options
Cite
Heitzmann E, Javelot H, Weiner L, et al. A Case of Aripiprazole-Induced Tardive Dyskinesia with Dramatic Evolution. Case Rep Psychiatry. 2016;2016:7031245doi: 10.1155/2016/7031245.
Heitzmann, E., Javelot, H., Weiner, L., & Michel, B. (2016). A Case of Aripiprazole-Induced Tardive Dyskinesia with Dramatic Evolution. Case reports in psychiatry, 20167031245. https://doi.org/10.1155/2016/7031245
Heitzmann, Edwige, et al. "A Case of Aripiprazole-Induced Tardive Dyskinesia with Dramatic Evolution." Case reports in psychiatry vol. 2016 (2016): 7031245. doi: https://doi.org/10.1155/2016/7031245
Heitzmann E, Javelot H, Weiner L, Michel B. A Case of Aripiprazole-Induced Tardive Dyskinesia with Dramatic Evolution. Case Rep Psychiatry. 2016;2016:7031245. doi: 10.1155/2016/7031245. Epub 2016 Oct 12. PMID: 27818825; PMCID: PMC5080510.
Copy Download .nbib Format: NLM
Share it on

Case Rep Psychiatry. 2016;2016:7031245. doi: 10.1155/2016/7031245. Epub 2016 Oct 12.

A Case of Aripiprazole-Induced Tardive Dyskinesia with Dramatic Evolution.

Case reports in psychiatry

Edwige Heitzmann, Hervé Javelot, Luisa Weiner, Bruno Michel

Affiliations

  1. North Alsace Mental Health Clinic (Etablissement Public de Santé Alsace Nord (EPSAN)), Brumath, France.
  2. Psychiatry Department, University Hospital of Strasbourg, Strasbourg, France.
  3. OMEDIT Alsace, Faculté de Pharmacie-Laboratoire HuManiS (EA 7308), Service Pharmacie-CHRU de Strasbourg, Strasbourg, France.

PMID: 27818825 PMCID: PMC5080510 DOI: 10.1155/2016/7031245

Abstract

Aripiprazole is reported to be a good clinical safety profile antipsychotic. However, recent data suggest that the risk of tardive dyskinesia could be higher than initially thought. We report the case of aripiprazole-induced tardive dyskinesia with dramatic evolution in a patient with several risk factors, including older age and exposure to antipsychotic over a period longer than six months. This case and its dramatic evolution, associated with other cases recently published, suggest reconsidering the real risk of tardive dyskinesia associated with aripiprazole, particularly in the elderly.

References

  1. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):571-2 - PubMed
  2. Aust N Z J Psychiatry. 2013 Mar;47(3):289-90 - PubMed
  3. P T. 2008 Jan;33(1):32-4 - PubMed
  4. J Clin Psychiatry. 2010 Apr;71(4):463-74 - PubMed
  5. Clin Psychopharmacol Neurosci. 2014 Apr;12(1):69-71 - PubMed
  6. CNS Drugs. 2015 Sep;29(9):773-99 - PubMed
  7. Acta Neuropsychiatr. 2011 Aug;23(4):188-90 - PubMed
  8. Biol Psychiatry. 2003 Jun 15;53(12):1142-5 - PubMed
  9. Mov Disord. 2011 Jan;26(1):147-52 - PubMed
  10. Can J Psychiatry. 2003 Dec;48(11):771-2 - PubMed
  11. J Neuropsychiatry Clin Neurosci. 2012 Summer;24(3):E44 - PubMed
  12. Psychopharmacology (Berl). 2016 Apr;233(8):1415-26 - PubMed
  13. Neuropsychopharmacology. 2008 Dec;33(13):3111-25 - PubMed
  14. Am J Psychiatry. 2007 Sep;164(9):1411-7 - PubMed
  15. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Oct 1;31(7):1535-6 - PubMed

Publication Types